3. Common adverse events in TNBC patients treated with ECdd-P/PCdd chemotherapy.
| Adverse events | n (%) | P* | |||
| ECdd-P arm (n=73) | PCdd arm (n=70) | ||||
| A patient could have experienced more than one specific toxicity. TNBC, triple-negative breast cancer; ECdd-P, dose-dense epirubicin and cyclophosphamide followed by paclitaxel; PCdd, dose-dense paclitaxel plus carboplatin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; CRE, creatinine; *, P values for differences in two arms are tested by χ2 test or Fisher exact test. | |||||
| Hematologic toxicities | Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | Grade 3/4 |
| Anemia | 28 (38.4) | 0 (0) | 14 (20.0) | 0 (0) | − |
| Leukopenia | 39 (53.4) | 26 (35.6) | 39 (55.7) | 12 (17.1) | 0.010 |
| Neutropenia | 30 (41.1) | 35 (47.9) | 31 (44.3) | 15 (21.4) | 0.001 |
| Thrombocytopenia | 8 (11.0) | 0 (0) | 9 (12.9) | 2 (2.9) | 0.238 |
| Non-hematologic toxicities | Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | Grade 3/4 |
| Alopecia | 36 (49.3) | 8 (11.0) | 32 (45.7) | 4 (5.7) | 0.204 |
| Stomatitis | 38 (52.1) | 0 (0) | 29 (41.4) | 0 (0) | − |
| Nausea emesis | 65 (89.0) | 0 (0) | 56 (80.0) | 1 (1.4) | 0.490 |
| Diarrhea | 5 (6.8) | 1 (1.4) | 1 (1.4) | 0 (0) | 0.490 |
| Mucositis/cutaneous | 3 (4.1) | 1 (1.4) | 1 (1.4) | 0 (0) | 0.490 |
| Peripheral neuropathy | 28 (38.4) | 1 (1.4) | 31 (44.3) | 4 (5.7) | 0.170 |
| Foot and hand syndrome | 6 (8.2) | 0 (0) | 1 (1.4) | 0 (0) | − |
| Myalgia/arthralgia | 12 (16.4) | 1 (1.4) | 11 (15.7) | 0 (0) | 0.490 |
| Asthenia | 8 (11.0) | 1 (1.4) | 6 (8.6) | 0 (0) | 0.490 |
| Allergic | 1 (1.4) | 0 (0) | 3 (4.3) | 0 (0) | − |
| Cardiac toxicity | 3 (4.1) | 0 (0) | 2 (2.9) | 0 (0) | − |
| ALT elevation | 25 (34.2) | 3 (4.1) | 19 (27.1) | 1 (1.4) | 0.326 |
| AST elevation | 30 (41.1) | 0 (0) | 26 (37.1) | 0 (0) | − |
| TBIL elevation | 29 (39.7) | 0 (0) | 26 (37.1) | 0 (0) | − |
| CRE elevation | 3 (4.1) | 0 (0) | 7 (10.0) | 0 (0) | − |